2018年8月27日 · In a multicenter, international, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 441 patients with transthyretin amyloid cardiomyopathy in a 2:1:2 ratio to receive 80 mg...

2024年7月25日 · Tafamidis (brand names Vyndaqel and Vyndamax) is a transthyretin stabilizer that may be given to reduce death or hospitalization caused by heart problems in adults with cardiomyopathy (damage of the heart muscle) caused by wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM).

2024年4月6日 · After 12- and 30-months of treatment, higher proportions of patients taking tafamidis 80 mg (n=176 at baseline) than placebo (n=177) showed improvement in 6MWT distance, KCCQ-OS score, PGA of overall health, and NT-proBNP concentration (Figure).

2023年5月29日 · Tafamidis is an oral medication for treating cardiomyopathy and peripheral neuropathy due to transthyretin amyloidosis (ATTR). It is a transthyretin stabilizer and has been shown to reduce disease progression and mortality significantly.

Conclusion: Tafamidis, both 80 and 20 mg, effectively reduced mortality and cardiovascular-related hospitalizations in patients with ATTR-CM. The longer-term survival data and the lack of dose-related safety concerns support tafamidis 80 mg as the optimal dose.

Tafamidis is an effective treatment for transthyretin amyloid cardiomyopathy (ATTR‐CM) in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT). While ATTR‐ACT was not designed for a dose‐specific assessment, further analysis from ATTR‐ACT and its long‐term extension study (LTE) can guide determination of the optimal dose.

Tafamidis, sold under the brand names Vyndaqel and Vyndamax, [5] is a medication used to delay disease progression in adults with certain forms of transthyretin amyloidosis. It can be used to treat both hereditary forms, familial amyloid cardiomyopathy and familial amyloid polyneuropathy , as well as wild-type transthyretin amyloidosis , which ...

2024年9月6日 · Detailed Tafamidis dosage information for adults. Includes dosages for Amyloidogenic Transthyretin Amyloidosis; plus renal, liver and dialysis adjustments.

2024年10月1日 · Tafamidis is used to treat cardiomyopathy (enlarged and thickened heart muscle) of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce death and hospitalization related to heart problems.

Tafamidis is indicated for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Treatment should be initiated under the supervision of a cardiologist knowledgeable in the management of patients with amyloidosis or cardiomyopathy.